基质金属蛋白酶9的表达是非霍奇金淋巴瘤患者的一个预后因素。

Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non-Hodgkin lymphoma.

作者信息

Sakata Koh-ichi, Satoh Masaaki, Someya Masanori, Asanuma Hiroko, Nagakura Hisayasu, Oouchi Atushi, Nakata Kensei, Kogawa Katsuhisa, Koito Kazumitsu, Hareyama Masato, Himi Tetsuo

机构信息

Department of Radiology, Sapporo Medical University, School of Medicine, S1W16 Chuo-Ku, Sapporo 060-8543, Japan.

出版信息

Cancer. 2004 Jan 15;100(2):356-65. doi: 10.1002/cncr.11905.

DOI:10.1002/cncr.11905

PMID:14716772

Abstract

BACKGROUND

Non-Hodgkin lymphoma (NHL) represents a heterogeneous group of tumors that vary with regard to their biologic aggressiveness and clinical course. In in vitro studies, matrix metalloproteinase 9 (MMP9) was reportedly expressed by human NHL cells and elevated levels of MMP9 have been observed in a subset of patients with high-grade NHL.

METHODS

The expression of MMP2 and MMP9 was evaluated in 158 patients with NHL and the relation between the expression of these proteins and clinicopathologic factors was analyzed. All but 1 patient had received radiation therapy and 92 patients also were treated with intensive combination chemotherapy.

RESULTS

Nearly all the patients with extranodal natural killer NK/T-cell lymphoma nasal type and anaplastic large cell lymphoma, T-cell/null cell type expressed MMP9. In contrast, only a small fraction of the patients with mucosa-associated lymphoid tissue (MALT) lymphomas and follicular lymphomas expressed MMP9. Approximately 50% of the diffuse large B-cell lymphoma (DLBCL) cases expressed MMP9. The expression of MMP2 was noted in some of the patients with DLBCL and nasal NK/T-cell lymphoma. The overall survival rates of patients who expressed MMP9 were significantly lower than that of those who did not. Such a correlation was not demonstrated in MMP2 expression. When MMP9 expression was analyzed in DLBLC patients, the overall survival rates of patients who expressed MMP9 were significantly lower than those who did not express MMP9. Chemotherapy was associated with better overall survival in DLBCL patients who expressed MMP9. Overall survival rates of T-cell/NK-cell lymphoma patients who expressed MMP9 appeared to be lower than that in those who did not express MMP9. However, chemotherapy was not found to improve overall survival in patients who expressed MMP9.

CONCLUSIONS

MMP9 expression was observed in patients with aggressive NHL and was characterized by poor overall survival.

摘要

背景

非霍奇金淋巴瘤（NHL）是一组异质性肿瘤，其生物学侵袭性和临床病程各不相同。据报道，在体外研究中，人NHL细胞表达基质金属蛋白酶9（MMP9），并且在一部分高级别NHL患者中观察到MMP9水平升高。

方法

评估了158例NHL患者中MMP2和MMP9的表达情况，并分析了这些蛋白表达与临床病理因素之间的关系。除1例患者外，所有患者均接受了放射治疗，92例患者还接受了强化联合化疗。

结果

几乎所有结外鼻型自然杀伤NK/T细胞淋巴瘤和间变性大细胞淋巴瘤（T细胞/裸细胞型）患者均表达MMP9。相比之下，只有一小部分黏膜相关淋巴组织（MALT）淋巴瘤和滤泡性淋巴瘤患者表达MMP9。大约50%的弥漫性大B细胞淋巴瘤（DLBCL）病例表达MMP9。在一些DLBCL和鼻NK/T细胞淋巴瘤患者中发现了MMP2的表达。表达MMP9的患者总生存率明显低于未表达者。MMP2表达未显示出这种相关性。在DLBLC患者中分析MMP9表达时，表达MMP9的患者总生存率明显低于未表达MMP9的患者。化疗与表达MMP9的DLBCL患者更好的总生存率相关。表达MMP9的T细胞/NK细胞淋巴瘤患者总生存率似乎低于未表达者。然而，未发现化疗能提高表达MMP9患者的总生存率。